Meeting
2018 ASCO Annual Meeting
GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.
Authors
Jonathan Back
Glenmark Pharmaceuticals SA, La Chaux-De-Fonds, Switzerland
Jonathan Back , Martin Wermke , Julie Macoin , Amelie Croset , John S. Kauh , Venkateshwar Reddy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Immunobiology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12053)
DOI
10.1200/JCO.2018.36.15_suppl.12053
Abstract #
12053
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
MT-5111: A novel HER2 targeting engineered toxin body in clinical development.
First Author: Roger J. Waltzman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
First Author: Fei Ma